A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Benlysta May Lead Wave Of New Approvals For Lupus Drugs," features profiles of Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol. Plus these Start-Ups Across Health Care: biocrea, e(ye)BRAIN, MiCardia and Omthera Pharmaceuticals
The looming approval of Benlysta may create an easier pathway to approval for other lupus candidates, while leaving a potentially broad opportunity for other drugs to fill gaps in its label.
While systemic lupus erythematosus is characterized by widespread inflammation, it is also a disease that correlates so frequently with kidney...